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Serum complement function was evaluated in 125 aﬀected subjects suﬀering from drinking water arsenic toxicity. Their mean
duration of exposure was 7.4 ± 5.3yrs, and the levels of arsenic in drinking water and urine samples were 216 ± 211 and 223 ±
302μg/L, respectively. The mean bactericidal activity of complement from the arsenic patients was 92% and that in the unexposed
controls was 99% (P<0.01), but heat-inactivated serum showed slightly elevated activity than in controls. In patients, the mean
complement C3 was 1.56g/L, and C4 was 0.29g/L compared to 1.68g/L and 0.25g/L, respectively, in the controls. The mean
IgG in the arsenic patients was 24.3g/L that was highly signiﬁcantly elevated (P<0.001). Arsenic patients showed a signiﬁcant
direct correlation between C3 and bactericidal activity (P = 0.014). Elevated levels of C4 indicated underutilization and possibly
impaired activity of the classical complement pathway. We conclude reduced function of serum complement in drinking water
arsenic toxicity.
1.Introduction
Drinking water contamination with high levels arsenic in
Bangladesh is the largest mass poisoning of a population
in history, with millions of people exposed [1]. The mean
arsenic concentrations in the drinking water of the exposed
populations in Bangladesh are more than twenty times
higher [2] than the maximum permissible limit recom-
mended by the Environmental Protection Agency of the USA
that has set the level at 10 micrograms per liter or 10 parts
per billion. A total of 61 out of 64 districts in Bangladesh
are already aﬀected with high levels of arsenic in ground
water. We found melanosis with black/white pigmentation
on skin, keratosis, lump, and nodule formation on feet and
hands in people chronically exposed to high levels of arsenic
in drinking water [2]. It had been reported that symptoms of
chronic arsenic toxicity develop insidiously after 6 months to
2 years or more of exposure [3].
The general adverse health eﬀects associated with human
exposure to arsenicals include cardiovascular diseases, devel-
opmental abnormalities, neurologic and neurobehavioral
disorders, diabetes, ﬁbrosis of the liver and lung, and
haematological disorders [4]. We reported, that apart from
the classical arsenical skin lesions, a large proportion of
arsenicosis patients had breathing problems, gastric and
abdominal pain, backache, headache, pain all over the body,
palpitation, anemia, and weakness. Arsenic toxicity caused
respiratorycomplications[5],modulationofserummetabo-
lites [6], and aﬀected the immune system with low leukocyte
count[2],andelevatedlevelsofserumimmunoglobulins[5].
However,thefunctionsofserumcomplementshavenotbeen
studied in the arsenicosis patients suﬀering from such a wide
range of complications.
The complement system plays an important role in
defense against pyogenic infections. Complements are innate
components of the immune system whose activation leads
to robust and eﬃcient proteolytic cascades, which terminate
in opsonization and lysis of the pathogen as well as in the
generation of the classical inﬂammatory response through
the production of potent proinﬂammatory molecules [7].
Complement activation also participates in clearance of
apoptotic cells and immune complexes. Recently, it was also
recognized that complement plays a key role in adaptive
immunity by modulating and modifying the T-cellresponses
[8]. Therefore, the complement systems may be regarded as
a link between innate and adaptive immunity and is critically2 Journal of Toxicology
involved in the pathogenesis and prevention of immune
complex diseases, such as systemic lupus erythematosus
(SLE) [9].
The immunotoxicity of heavy metals has not been
extensively studied. Bernier et al. [10] found that heavy
metals including mercury, lead, and cadmium present in
small amounts in the Great Lakes water and ﬁsh and
exposure of humans to these metals via the ingestion
of contaminated food especially ﬁsh alter a number of
parameters of the host’s immune system leading to increased
susceptibility to infections, autoimmune diseases, and aller-
gic manifestations. In another study, it was found that
mercury can induce autoimmune disease both in humans
and experimental animals, while cadmium treatment of rats
and mice results in autoimmune responses that vary with
species and inbred strain of animals [11]. The peripheral
blood neutrophils of workers occupationally exposed to
lead showed reduced chemotaxis and nitroblue tetrazolium
dye reduction, suggesting immune dysfunction may be a
sensitive indicator of lead exposure [12]. In view of lack of
information on the humoral immune response, this study
was designed to evaluate serum complement function in
arsenicosis patients.
2.MaterialsandMethods
2.1. Study Area. The study areas of this investigation were
the arsenic endemic rural villages of Rajarampur, Achinpara,
Chandnai, and Bottola under the northwestern district of
Chapainawabganj where arsenic contamination in drinking
water was ﬁrst detected in Bangladesh in 1993 and the village
Ilumdi under Araihazar of Narayanganj that is about 35km
southeast of the capital city Dhaka.
2.2. Arsenicosis Patient Inclusion Criteria. Subjects consum-
ing drinking water that contained arsenic levels greater than
the tolerable limit recommended by the WHO (50μg/L), not
taking medicine for any illness, and having signs of arsenic
toxicity were enrolled in this study as the patients. Their
source of drinking water was tube well or artisan well. The
signs of arsenic toxicity (arsenicosis) were assessed on the
basis of appearance of skin lesions [2, 5, 6]. After informed
consent,theresearcherswiththehelpofapublichealthnurse
interviewed all the patients personally. The information on
symptoms and complications of arsenic toxicity, duration of
exposure, anthropometric parameters including age, height,
and body weight of the patients were recorded on preformed
questionnaires.
2.3. Sample Collection. Blood samples (about 3mL) were
collected from the subjects with their full consent to partici-
pate in this study. A total of 250 blood samples were collected
of which 125 were from patients with arsenic toxicity
(arsenicosis), 95 from unexposed subjects living in the same
area as the patients but drinking safe water and with no
sign of arsenic toxicity, and the remaining from unexposed
subjects living in the city. Spot urine and drinking water
sampleswerealsocollectedfromeachindividual.Allsamples
were collected in fresh, sterile universals. The blood sample
was allowed to clot, and serum was separated immediately
after collection. The frozen sera were transported to the
laboratory in ice-packed containers and stored at −80◦C
until analyzed.
2.4. Analyses of Arsenic. Concentrated nitric acid was mixed
with the drinking water samples at 1mL per liter and
stored at 4◦C until analyzed. The urine samples were frozen
immediately after collection. Arsenic content in the water
and urine samples were measured following the standard
procedurebyusingaFlowInjection—HydrideGeneration—
Atomic Absorption Spectrophotometer, and the results were
expressed in μg/L.
2.5. Assay of Complement-Mediated Bactericidal Activity.
Escherichia coli DH5α was grown in nutrient broth for
14 hour at 37◦Ci na no r b i t a ls h a k e r .T h eb a c t e r i a lc e l l s
were harvested, washed two times using excess of PBS
and then the suspension was adjusted to 0.600O.D. at
620nm. Immediately, aliquots of 200μL of the bacterial cell
suspensions (BCS) were taken into separate tubes, 20μL
of serum was added to each tube, and the mixture was
incubated for 30 minutes at 37◦C. At the end of incubation,
the remaining viable cells were serially diluted with PBS to
1:10,000. An aliquot of 20μL of this dilution was spread on
each of 3 agar plates and incubated for 16 hours at 37◦C. The
number of colonies formedwas counted, and the mean value
for each serum was taken from the readings of 3 plates. For
the negative control experiments, 20μL of PBS (medium)
was added to the BCS instead of serum, incubated, and then
serially diluted with PBS to 1:50,000. An aliquot of 20μLo f
this dilution was spread on each of 3 agar plates.
2.6. Assay of Complement-Inactivated Bactericidal Activity.
Complement proteins were inactivated by heat treatment at
56◦C for 30 minutes in a water bath and then used (20μL)
to test for bactericidal activity. Both the PBS (control) and
bacteria treated with inactivated serum preparations were
serially diluted to 1:50,000. The rest of the procedure was
as described before.
2.7. Calculation of Bactericidal Activity. Bactericidal activity
was calculated using the following formula, as described
elsewhere [13, 14]. For the control, if the mean colony-
forming unit (cfu) on the plate was Nc, then 1mL of the
original bacterial cell suspension contained Nc × 50 ×
50,000cfu.
For the test serum, if the mean cfu on the plate was Ns,
then 1mL of the bacterial cell suspension treated with serum
complement contained Ns × 50 × 10,000cfu. Therefore,
%bactericidal activity
=
(Nc ×50 ×50,000) −(Ns × 50 ×10,000)
Nc ×50 ×50,000
×100.
(1)Journal of Toxicology 3
The bactericidal activity (%) of the inactivated serum for the
mean cfu, Ni, was
(Nc ×50 ×50,000) −(Ni ×50 ×50,000)
Nc ×50 ×50,000
×100. (2)
2.8. Determination of Serum C3, C4, and IgG. Quantitative
estimates of serum complement components C3 and C4
were performed using a TURBOX plus Analyzer, Orion
Diagnostica,Finland.Themethodwasbasedontheprinciple
of immunoprecipitation reaction of a speciﬁc antibody with
its antigen. The light scattering caused by antigen-antibody
complexes was measured after incubation. The intensity of
the scattered light was directly proportional to the con-
centration of the tested complement protein present in the
serum sample. IgG was measured by immunonephelometry
using DADE Behring reagents (USA) and an autoanalyzer.
The procedure was according to the supplier’s recommended
protocol. The results were expressed in g/L.
2.9. Statistical Analysis. Data analyses were carried out
using the Statistical Package for Social Sciences (SPSS).
The methods used were independent t-test for comparison
of two groups (arsenicosis patients and control subjects),
Pearson correlations, and simple statistics. The results were
considered signiﬁcant when P was ≤0.05.
3. Results
3.1. Baseline Characteristics of the Study Subjects. The base-
linecharacteristicsshowedtheageofthepatientsvariedfrom
14–65 yrs, and the mean body mass index (BMI) was 20.9 ±
3.5. In the control subjects, the age varied from 19 to 72 yrs,
and the mean BMI was 22.4 ± 2.7. The whole population
of patients had a mean monthly family income of about
Bangladeshi Taka 5,000 (about USD 80) that varied from
Taka 1,000–16,000. About one-third of the patients had no
formal education; while 30% attended primary schools and
the remaining had secondary school and higher education.
The number of family members of the patients varied from
2t o9w i t ham e a nv a l u eo f5 . 0± 1.5. Of the unexposed
subjects, only about 5% were illiterate, while the education
levels of the rest were from primary to higher. The monthly
family income of the controls varied from Taka 1,500–25,000
with a mean of about Taka 7,000 (USD 112). Their family
members varied from 2 to 6.
3.2. Clinical Symptoms and Complications of Arsenic Toxicity.
The clinical symptoms based on skin manifestations were
recorded on questionnaire after interviewing and careful
examination of the subjects. The symptoms included dif-
fused and spotted melanosis with black and white appear-
ances, rough and mottled skin, keratosis or hardening of
the soles and palm with often formation of nodules and
cracks. Spotted melanosis was more often seen on the throat,
chest, back, or limbs. The duration of exposure has been
found directly related to the severity of clinical disease.
About one-third of the patients suﬀered from severe skin
irritation including itchy rash. There was high prevalence
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Figure 1: Number of Escherichia coli DH5α colonies (million
cfu/mL) grown on agar plates from the bacterial cell suspension in
PBS (Medium) and after the action of serum complements from
healthy controls and arsenic patients. Before plating, the bacterial
cell suspensions were diluted with PBS to 1:50,000 in Medium, and
1:10,000 both for serum samples from control subjects and arsenic
patients. Compared with the Medium, complements from both the
sera exhibited highly signiﬁcant bacteriolytic eﬀects (P<0.001),
while complements from arsenic patients showed signiﬁcantly
diminished bacteriolytic eﬀects compared to the control subjects
(P<0.001).
of respiratory complications including asthma, bronchitis
and cough. Long-term exposure to arsenic also caused
conjunctivitis, disturbances in the peripheral vascular and
nervoussystems,andgangreneofthelimbs.Thepatientshad
the mean duration of arsenic exposure for 7.4 ± 5.3 yrs that
varied from 1 to 25 yrs with a median of 6.0 yrs.
3.3. Levels of Arsenic in the Drinking Water and Urine
Samples. It was found that the drinking water of the patients
contained 67–875μg/L of arsenic with the mean value of
216.2 ± 210.6μg/L and median of 156μg/L. The mean level
of arsenic in the spot urine samples of the patients was
223.2 ± 302.4μg/L, while the median was 114.0μg/L and
the maximum value was 1764μg/L. On the other hand, the
mean arsenic concentrations in the drinking water and urine
samples of the unexposed (control) populations were 11.3
and 29.4μg/L, respectively. Statistical analysis showed the
levels of arsenic in the drinking water and urine samples of
the patients were highly positively correlated (P<0.001).
3.4. Complement-Mediated Bactericidal Activity. It was
found that the numbers of Escherichia coli DH5α colonies
grown on agar plates without treating the bacterial cell
suspensions with serum complement (PBS alone, negative
control) varied from 401–978 × 106 cfu/mL with a median
of 714.5 × 106 cfu/mL. On the other hand, the numbers
of colonies formed after treating the BCS with serum
complements from control healthy subjects varied from 1.1–
54.8 × 106 cfu/mL with a median of 4 × 106 cfu/mL, and,
aftertreatingwithserumcomplementsfromarsenicpatients,
the number of colonies varied from 1.5–570 × 106 cfu/mL
with a median of 47.3 × 106 cfu/mL (Figure 1). Compared4 Journal of Toxicology
Table 1: Complement-mediated and complement-inactivated bac-
tericidal activities in the serum of arsenic patients and control
subjects.
Study subjects
% Bactericidal activity (mean ± SD)
Complement-
mediated
Complement
inactivated
Arsenic patients N = 125
92.1 ± 16.0 19.4 ± 8.6
Median: 97.3 Median: 18.6
Range: 24.6–99.9 Range: 3.3–33.0
Control subjects N = 125
99.1 ± 1.4 18.2 ± 6.9
Median: 99.4 Median: 17.1
Range: 92.2–100 Range: 6.2–35.3
Statistics (P value) <0.01 NS
to the negative control experiments, complements from
both healthy subjects and arsenic patients exhibited highly
signiﬁcant bacteriolytic eﬀects (P<0.001). However,
complements from arsenic patients showed signiﬁcantly
diminished bacteriolytic eﬀects (assessed by the large num-
ber of cfu) compared to the control subjects (P<0.001).
The bactericidal activity of complements from the arsenic
patients varied widely from 24.6 to 99.9% compared to
92.2–100% in the control healthy subjects (Table 1). The
complement-mediated bactericidal activity of the arsenic
patients was signiﬁcantly lower than that of the control
subjects (P<0.01).
3.5. Eﬀect of Complement-Inactivation on Bactericidal Activ-
ity. The bactericidal activity of the complement-inactivated
serum from the control subjects varied from 6.2 to 35.3%
whereas that from the arsenic patients varied from 3.3 to
33.0%. These results presented in Table 1 indicated that the
complement-inactivated bactericidal activity of the arsenic
patients was not signiﬁcantly diﬀerent from that of the
control subjects.
3.6. Levels of Complement Component C3. It was found that,
of the total arsenic patients, about 93% had normal levels
of serum complement component C3 (normal level: 0.9–
2.1g/L) whereas 5% had above normal, and only 2% had
below normal levels. On the other hand, 85% of the control
subjects had normal levels, and the remaining 15% had
above normal levels of serum complement C3. The mean
level of C3 in the arsenic patients was 1.56 ± 0.36g/L and
that in the healthy control subjects was 1.68 ± 0.35g/L.
These results showed arsenic patients had lower levels of
serum complement component C3 than the healthy subjects
(Table 2).
3.7. Levels of Complement Component C4. T h el e v e l so f
complement component C4 in about 20% of the patients
were found to be above normal. The remaining patients
had serum C4 levels within the normal value (0.1–0.4g/L).
Among the control subjects, 90% had normal C4, 4% had
above normal and the remaining 6% had below normal
levels. The whole population of patients had the mean C4
level of 0.29 ± 0.11g/L while that in the healthy control
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Figure 2: Correlation between the levels of serum complement C3
(g/L) from arsenicosis patients with bactericidal activity (bacterial
killing,%)onEscherichiacoliDH5αcells.Theﬁgureshowsbacterial
killing decreased as the levels of C3 decreased in arsenic toxicity,
giving a direct correlation (P = 0.014).
subjectswas0.25 ±0.11g/L.Thesedatashowedalthoughthe
diﬀerences were not signiﬁcant (P<0.06), the complement
component C4 levels in the arsenic patients were higher than
that in the control subjects (Table 2).
3.8. Correlation of the Levels of C3 with Bactericidal Activity.
It was found that about one-third of the total arsenic
patients tended to have lower levels of C3; however, these
values were around the lower limit of the normal range
showing a mean value of 1.19 ± 0.42g/L with corresponding
bactericidal activity of 67.4 ± 20.2%. Analysis of the whole
population data (N = 125) showed a signiﬁcant direct
correlation between the levels of C3 and complement-
mediated bactericidal activity (P = 0.014) among the
arsenicosis patients (Figure 2).
3.9. Levels of Serum IgG. To ﬁnd out an explanation whether
immunoglobulin G (IgG) was responsible for enhanced
killing of bacteria after complement inactivation, IgG levels
were measured in the fresh serum. It was found that arsenic
patients had the mean serum IgG level of 24.3 ± 7.5g/L
compared to 13.8 ± 7.8g/L in the healthy control subjects
(normal level: 7.0–16.0g/L). Statistical analysis showed IgG
levels in the arsenicosis patients were signiﬁcantly higher
than that in the control subjects (P<0.001). The results are
shown in Table 2.
4. Discussions
Millions of people worldwide are chronically exposed to
arsenic through drinking water, including an estimated 35–
77 million people in Bangladesh [15]. In the present study,Journal of Toxicology 5
Table 2: Levels of serum complements C3 and C4 and immunoglobulin G in the arsenic patients and control subjects.
Study subjects
Concentration in serum: (Mean ± SD) g/L
Complement C3
NV: 0.9–2.1
Complement C4
NV: 0.1–0.4
Immunoglobulin G
NV: 7.0–16.0
Arsenic patients N = 125
1.56 ± 0.36 0.29 ± 0.11 24.3 ± 7.5
Median: 1.56 Median: 0.27 Median: 22.7
Range: 0.16–2.50 Range: 0.1–0.57 Range: 7.7–49.3
Control subjects N = 125
1.68 ± 0.35 0.25 ± 0.11 13.8 ± 7.8
Median: 1.67 Median: 0.22 Median: 10.8
Range: 0.9–2.64 Range: 0.05–0.49 Range: 4.2–31.6
Statistics (P value) NS NS (0.06) <0.001
NV: normal value; NS: not signiﬁcant.
skin manifestations have been found as the prime and
common features of arsenic toxicity that has been considered
as deﬁnite exposure [2]. About 27% of the enrolled patients
had BMI lower than 18.5 compared to only 6% of the
control subjects. Thus, a relation between arsenic toxicity
and poor nutritional status (low BMI) was conﬁrmed in
the present study, as described earlier [2]. It had been
reported that infection could rapidly lead to nutritional
stress and weight loss, thereby worsening nutritional status
and immunologic function [16–18]. In a prospective cohort
study on 14 patients with severe anorexia nervosa having
BMI less than 14.0, serum complement C3 levels were found
signiﬁcantly lower than in the healthy controls [19]. We
found a direct correlation, though marginally insigniﬁcant,
between nutritional status (BMI) and serum complement
protein C3 in the arsenicosis patients (P = 0.057). Poor
nutritional status of the aﬀected subjects might have a role
in high retention of arsenic in the body.
Measurements of complement proteins C3 and C4 aid
in the diagnosis of immunologic disorders, especially those
associated with deﬁciencies of complement components.
The proteins of complement system play important role
in the innate immune response. The results of some
clinical studies have suggested that complement activation
exacerbated myocardial defect following ischaemic injury
[20], has been involved in the generation of spontaneous
atheroscleroticlesions,andmayindeedbeaninitiatingfactor
in lesion formation [21]. Assessment of the complement
C3 and C4 concentration ratio (C3/C4 ratio) in serum
has been suggested as a potential measurement to predict
cardiovascularattacks[22].Newstudiespointtothecomplex
interplay between the complement cascade and adaptive
immune response, and complement is also being studied in
association with ischemic injury as a target of therapy [9].
Escherichia coli DH5α used in this study is a non-
pathogenic bacterium, and, therefore, no appreciable levels
of speciﬁc antibody should be present in the sera of human
subjects against this organism. Therefore, killing of bacteria
wouldbesolelyduetoserumcomplement.Wefoundthatthe
complement-mediated bactericidal activity in the patients
was signiﬁcantly lower than that in the control group. We
alsofoundthe concentrationof C3in the arsenicosispatients
was lower but that of C4 was higher, although none was
signiﬁcantly diﬀerent than in the control subjects. However,
about one-third of the arsenic patients had signiﬁcantly
lower values of C3 compared to the controls (P<0.001).
These sera containing lower levels of C3 showed highly
signiﬁcantly reduced bactericidal activity (67.4 ± 20.2%)
compared to the healthy controls (99.1 ± 1.4%) and showed
av a l u eo fP<0.001.
ThelowerlevelsofC3inthearsenicpatientsmightbethe
reason for reduced complement function since a signiﬁcant
direct correlation was found between the levels of C3 and
complement-mediated bactericidal activity (P = 0.014). The
complement-inactivated bactericidal activity of the patients
was similar to that of the control group. We reported earlier
that the arsenic patients had signiﬁcantly elevated levels of
serum IgG, IgA, and IgE [5]. Since the arsenic patients
suﬀer from melanosis, keratosis, cracks on foot soles and
palmsthatmightharborbacterialinfections,theirseramight
containhighlevelsofIgGantibodiesagainsttheseorganisms.
These IgG antibodies might play a role in enhanced killing
of bacterial cells, while the serum complements had been
destroyed by heat inactivation. We reported similar ﬁndings
inthepulmonarytuberculosispatientswhohadchroniclung
infection [14].
The role of serum complement in immunotoxicity
of heavy metals remains poorly understood. It had been
reported in an old study that the lead workers had lower
serum complement C3 and immunoglobulins IgG, IgM
and IgA levels, as well as lower salivary IgA levels than
the reference subjects [23]. In another study, the eﬀects of
gallium arsenide (GaAs) exposure as a single intratracheal
dose on immunocompetence of B6C3F1 female mice were
investigated and found that GaAs aﬀected both humoral
and cellular immune parameters in the mice and impaired
the ability of the immune system to protect against B16F10
tumor challenge [24]. It had been found that bivalent
nickel or cobalt at concentrations below 100 micro-M could
stimulate the conversion of complement protein C3 to C3b
faster than magnesium, which was the natural cofactor in
thealternativepathwayofcomplementactivation,suggesting
that the increased rate of C3-fragment production induced
by nickel or cobalt ions was central for the immunotoxicity
of these metals [25].
Deﬁciencies of complement proteins are frequently asso-
ciated with an immunodeﬁciency state in which the patients
suﬀerwithrecurrentbacterialinfectionsfromorganismsthat6 Journal of Toxicology
are normally susceptible to opsonization or lysis by com-
plement. A recent study has shown low serum complement
level in chronic liver disease signiﬁcantly increases the risk of
spontaneousbacterialperitonitisinchildren[26].Inpatients
with nonalcoholic liver cirrhosis, serum bactericidal activity
had been found to be reduced and complement proteins C3
and C4 were found to have signiﬁcantly low values [27].
In the arsenicosis patients, suppressed complement function
m i g h tb ead i r e c te ﬀect of chronic arsenic toxicity. It may be
recalled that zymogen forms of complement protein C3 are
activated both by the alternative and classical complement
pathways, thereby making the activated fragment C3b takes
part in bactericidal activity by either or both of these
pathways.Ontheotherhand,complementC4takespartonly
in the classical pathway. Our ﬁnding of elevated levels of C4
in about 20% of the patients indicated underutilization of
complement C4 and hence possibly suppressed activity of
the classical complement pathway in drinking water arsenic
toxicity.
5. Conclusion
Lower levels of serum complement protein C3 in the
arsenicosis patients and reduced complement-mediated bac-
tericidal activity reveal serum complement functions are
suppressed in drinking water arsenic toxicity. The ﬁndings
from this preliminary study show immunotoxicity of arsenic
resulting impaired complement function that requires fur-
ther investigation on a large population.
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